香港股市 已收市

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
86.05+0.59 (+0.69%)
市場開市。 截至 09:42AM EDT。

BioNTech SE

An der Goldgrube 12
Mainz 55131
Germany
49 6131 9084 0
https://www.biontech.de

版塊Healthcare
行業Biotechnology
全職員工6,133

高階主管

名稱頭銜支付行使價出生年份
Dr. Ugur Sahin M.D.Co-Founder, CEO & Chair of the Management Board1.26M1965
Dr. Ozlem Tureci M.D.Co-Founder, Chief Medical Officer & Member of Management Board826.55k1967
Mr. Jens H. HolsteinCFO & Member of Management Board1.45M1963
Dr. Sierk Poetting Ph.D.MD, COO & Member of Management Board849.42k1973
Mr. Ryan RichardsonChief Strategy Officer, MD & Member of Management Board1.04M1979
Dr. James Timothy Patrick Ryan Ph.D.Chief Legal & Business Officer & Member of the Management Board614.2k1975
Mr. Sean MarettExecutive Officer820.02k1965
Mr. Zach TaylorSenior Vice President of Corporate Development & Strategy
Dr. Katalin Kariko Ph.D.Senior VP & External Consultant for RNA Protein Replacement Therapies
Dr. Oliver Henning Ph.D.Senior Vice President of Operations
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vaccine ecosystem. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

公司管治

截至 2024年7月1日 止,BioNTech SE 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中:2;董事會:4;股東權利:1;現金賠償:6。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。